Maternal human papillomavirus infection during pregnancy and preterm delivery: A mother-child cohort study in Norway and Sweden.


Journal

Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343

Informations de publication

Date de publication:
03 2023
Historique:
revised: 21 12 2022
received: 19 04 2022
accepted: 22 12 2022
pubmed: 18 1 2023
medline: 3 3 2023
entrez: 17 1 2023
Statut: ppublish

Résumé

Human papillomavirus (HPV) infection is common in women of reproductive age. Infection and inflammation are leading causes for preterm delivery (PTD), but the role of HPV infection in PTD and prelabor rupture of membranes (PROM) is unclear. We aimed to explore whether HPV infection during pregnancy in general, and high-risk-HPV (HR-HPV) infection specifically, increased the risk of PTD, preterm prelabor rupture of membranes (PPROM), PROM at term, and/or chorioamnionitis. In pregnant women, who were participating in a prospective multicenter cohort study from a general population in Norway and Sweden (PreventADALL, ClinicalTrials.gov NCT02449850), HPV DNA was analyzed in available urine samples at mid-gestation (16-22 weeks) and at delivery, and in the placenta after delivery with Seegene Anyplex II HPV28 PCR assay. The risk of PTD, PPROM, PROM, and chorioamnionitis was analyzed using unadjusted and adjusted logistic regression analyses for any 28 HPV genotypes, including 12 HR-HPV genotypes, compared with HPV-negative women. Further, subgroups of HPV (low-risk/possibly HR-HPV, HR-HPV-non-16 and HR-HPV-16), persistence of HR-HPV from mid-gestation to delivery, HR-HPV-viral load, and presence of multiple HPV infections were analyzed for the obstetric outcomes. Samples for HPV analyses were available from 950 women with singleton pregnancies (mean age 32 years) at mid-gestation and in 753 also at delivery. At mid-gestation, 40% of women were positive for any HPV and 24% for HR-HPV. Of the 950 included women, 23 had PTD (2.4%), nine had PPROM (0.9%), and six had chorioamnionitis (0.6%). Of the term pregnancies, 25% involved PROM. The frequency of PTD was higher in HR-HPV-positive women (8/231, 3.5%) than in HPV-negative women (13/573, 2.3%) at mid-gestation, but the association was not statistically significant (odds ratio 1.55; 95% confidence interval 0.63-3.78). Neither any HPV nor subgroups of HPV at mid-gestation or delivery, nor persistence of HR-HPV was significantly associated with increased risk for PTD, PPROM, PROM, or chorioamnionitis. No HPV DNA was detected in placentas of women with PTD, PPROM or chorioamnionitis. HPV infection during pregnancy was not significantly associated with increased risk for PTD, PPROM, PROM, or chorioamnionitis among women from a general population with a low incidence of adverse obstetric outcomes.

Identifiants

pubmed: 36647213
doi: 10.1111/aogs.14509
pmc: PMC9951315
doi:

Banques de données

ClinicalTrials.gov
['NCT02449850']

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

344-354

Subventions

Organisme : Freemason Child House Foundation in Stockholm
Organisme : Health and Rehabilitation Norway
Organisme : Oslo University Hospital
Organisme : Østfold Hospital Trust
Organisme : SFO-V at the Karolinska Institute
Organisme : Swedish Asthma and Allergy Association's Research Foundation
Organisme : Swedish Research Council for Health, Working Life and Welfare-FORTE
Organisme : Swedish Research Council-the Initiative for Clinical Therapy Research
Organisme : The Foundation for Healthcare and Allergy Research in Sweden-Vårdalstiftelsen
Organisme : The Norwegian Research Council
Organisme : The Regional Health Board South East, Norway
Organisme : The Swedish Heart-Lung Foundation
Organisme : the University of Oslo

Informations de copyright

© 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

Références

Lancet. 2012 Jun 9;379(9832):2151-61
pubmed: 22579125
Oncol Lett. 2015 Mar;9(3):1015-1026
pubmed: 25663851
JAMA Netw Open. 2021 Sep 1;4(9):e2125308
pubmed: 34524433
J Infect Dis. 2020 Jun 11;221(12):1925-1937
pubmed: 32022858
JAMA Netw Open. 2021 Jan 4;4(1):e2032779
pubmed: 33416885
Am J Reprod Immunol. 2014 Aug;72(2):107-16
pubmed: 24995526
Wellcome Open Res. 2019 Mar 8;4:48
pubmed: 30984880
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:2-13
pubmed: 28964706
Allergy. 2018 Oct;73(10):2063-2070
pubmed: 29710408
Cochrane Database Syst Rev. 2017 Nov 02;11:CD012847
pubmed: 29095502
J Immunol. 2013 Jul 15;191(2):934-41
pubmed: 23752614
BMC Pregnancy Childbirth. 2013 Sep 06;13:173
pubmed: 24011340
Int J Infect Dis. 2021 Jul;108:574-581
pubmed: 34077798
Am J Clin Pathol. 2011 Aug;136(2):260-5
pubmed: 21757599
Science. 2014 Aug 15;345(6198):760-5
pubmed: 25124429
Acta Obstet Gynecol Scand. 2023 Mar;102(3):344-354
pubmed: 36647213
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
Viruses. 2021 Jul 12;13(7):
pubmed: 34372548
MCN Am J Matern Child Nurs. 2013 Jul-Aug;38(4):206-12; quiz 213-4
pubmed: 23579417
Nat Commun. 2022 Jan 11;13(1):233
pubmed: 35017496
Infect Dis Obstet Gynecol. 2019 Mar 24;2019:4376902
pubmed: 31019362
Acta Obstet Gynecol Scand. 2018 Apr;97(4):466-476
pubmed: 29172245
PLoS Med. 2021 May 10;18(5):e1003641
pubmed: 33970907
Virology. 2013 Oct;445(1-2):224-31
pubmed: 23928291
Obstet Gynecol. 2016 Feb;127(2):233-40
pubmed: 26942348
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
Lancet. 2008 Jan 5;371(9606):75-84
pubmed: 18177778
N Engl J Med. 2008 Jul 17;359(3):262-73
pubmed: 18635431
BMJ. 2014 Sep 16;349:g5264
pubmed: 25232064
Hum Reprod. 2008 Mar;23(3):709-15
pubmed: 18184644

Auteurs

Johanna Wiik (J)

Department of Gynecology and Obstetrics, Østfold Hospital Trust, Gralum, Norway.
Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Magdalena R Vaernesbranden (MR)

Department of Gynecology and Obstetrics, Østfold Hospital Trust, Gralum, Norway.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Christine M Jonassen (CM)

Department of Virology, Norwegian Institute of Public Health Oslo, Oslo, Norway.
Genetic Unit, Center for Laboratory Medicine, Østfold Hospital Trust, Gralum, Norway.

Anne Cathrine Staff (AC)

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Division of Obstetrics and Gynecology, Oslo University Hospital, Oslo, Norway.

Karin C L Carlsen (KCL)

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Berit Granum (B)

Department of Chemical Toxicology, Norwegian Institute of Public Health, Oslo, Norway.

Guttorm Haugen (G)

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Division of Obstetrics and Gynecology, Oslo University Hospital, Oslo, Norway.

Gunilla Hedlin (G)

Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Katarina Hilde (K)

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Division of Obstetrics and Gynecology, Oslo University Hospital, Oslo, Norway.

Bo Jacobsson (B)

Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Genetics and Bioinformatics, Division of Health Data and Digitalization, Institute of Public Health, Oslo, Norway.

Staffan Nilsson (S)

Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden.

Björn Nordlund (B)

Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Anbjørg Rangberg (A)

Genetic Unit, Center for Laboratory Medicine, Østfold Hospital Trust, Gralum, Norway.

Eva Maria Rehbinder (EM)

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Department of Dermatology and Venereology, Oslo University Hospital, Oslo, Norway.

Verena Sengpiel (V)

Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Håvard Skjerven (H)

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Birgitte K Sundet (BK)

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Division of Obstetrics and Gynecology, Oslo University Hospital, Oslo, Norway.

Cilla Söderhäll (C)

Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Riyas Vettukattil (R)

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Katrine Sjøborg (K)

Department of Gynecology and Obstetrics, Østfold Hospital Trust, Gralum, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH